MBRX

Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

Moleculin Biotech to Present at the Q2 Virtual Investor Summit

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

MBRX Stock: Over 10% Pre-Market Explanation

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma